Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation
dc.contributor.author | Gutmann, D. H. | en_US |
dc.contributor.author | Tennekoon, Gihan I. | en_US |
dc.contributor.author | Cole, Jeffrey L. | en_US |
dc.contributor.author | Collins, Francis S. | en_US |
dc.contributor.author | Rutkowski, J. Lynn | en_US |
dc.date.accessioned | 2007-04-06T18:41:02Z | |
dc.date.available | 2007-04-06T18:41:02Z | |
dc.date.issued | 1993-10-01 | en_US |
dc.identifier.citation | Gutmann, D. H.; Tennekoon, G. I.; Cole, J. L.; Collins, F. S.; Rutkowski, J. L. (1993)."Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation." Journal of Neuroscience Research 36(2): 216-223. <http://hdl.handle.net/2027.42/50227> | en_US |
dc.identifier.issn | 0360-4012 | en_US |
dc.identifier.issn | 1097-4547 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/50227 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7505343&dopt=citation | en_US |
dc.description.abstract | Neurofibromin, the product of the neurofibromatosis type 1 (NF1) gene, is a ∼250 kDa protein expressed predominantly in cortical neurons and oligodendrocytes in the central nervous system (CNS) and sensory neurons and Schwann cells in the peripheral nervous system (PNS). To gain insight into the biological role of neurofibromin in Schwann cells, the modulation of NF1 gene expression in a Schwann cell line (MT 4 H1) stimulated to either proliferate or differentiate in response to agents that elevate intracellular cAMP was examined. Untreated cells and cells exposed to mitogenic doses of forskolin (1–10 ΜM) or 8-bromo-cAMP (0.1 mM) expressed low levels of NF1 MRNA and the protein was barely detectable. High doses of forskolin (100 ΜM) or 8-bromo-cAMP (1 mM) induced the expression of both myelin P 0 protein and neurofibromin with an identical time course. Although NF1 mRNA levels peaked within 1–6 hr, the rise in neurofibromin was not apparent until 24–48 hr and peaked 72 hr after treatment. P 0 and neurofibromin were also coinduced by cell-cell contact in high density, untreated cultures. Moreover, differentiation initiated by either cAMP stimulation or high density culture conditions was associated with predominant expression of the type 2 NF1 mRNA isoform. In contrast, type 1 NF1 mRNA isoform expression was observed in untreated Schwann cells or those stimulated with mitogenic doses of forskolin or 8-bromo-cAMP. A switch from the type 1 neurofibromin that can efficiently down-regulate p21-ras to the type 2 isoform with reduced activity may facilitate a p21-ras signaling pathway associated with Schwann cell difrerentiation. © 1993 Wiley-Liss, Inc. | en_US |
dc.format.extent | 822589 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Neuroscience, Neurology and Psychiatry | en_US |
dc.title | Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Psychology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Social Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Neurology, University of Michigan Medical Center, Ann Arbor ; Departments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor ; 4570 MSRB 2, Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109-0650 | en_US |
dc.contributor.affiliationum | Departments of Pediatrics, University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationum | Departments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationum | Departments of Human Genetics, University of Michigan Medical Center, Ann Arbor ; Departments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor | en_US |
dc.contributor.affiliationum | Departments of Pediatrics, University of Michigan Medical Center, Ann Arbor | en_US |
dc.identifier.pmid | 7505343 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/50227/1/490360212_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/jnr.490360212 | en_US |
dc.identifier.source | Journal of Neuroscience Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.